Medplus Health Services Intrinsic Value

Medplus Health Services (MEDPLUS) median intrinsic value is ₹822.92 from 9 valuation models (range ₹247–₹2055), vs current price ₹822.00 — +0.1% upside (Trading Near Calculated Value), margin of safety 0.1%. Read MEDPLUS dividend yield for the complete payout history and dividend yield track record.

Current Stock Price
₹822.00
Primary Intrinsic Value
₹255.84
Market Cap
₹1973 Cr
+0.1% Upside
Median Value
₹822.92
Value Range
₹247 - ₹2055
Assessment
Trading Near Calculated Value
Safety Margin
0.1%

MEDPLUS Valuation Methods Summary — DCF, Graham Number & P/E

Medplus Health Services intrinsic value across 9 models vs current price ₹822.00 — upside/downside and value range per method. For current market price and key ratios, visit Medplus Health Services stock price NSE.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹255.84 ₹204.67 - ₹307.01 -68.9% EPS: ₹21.32, Sector P/E: 12x
Book Value Method asset ₹822.92 ₹740.63 - ₹905.21 +0.1% Book Value/Share: ₹822.92, P/B: 1.0x
Revenue Multiple Method revenue ₹1644.00 ₹1479.60 - ₹1808.40 +100.0% Revenue/Share: ₹3141.67, P/S: 0.8x
EBITDA Multiple Method earnings ₹1644.00 ₹1479.60 - ₹1808.40 +100.0% EBITDA: ₹760.00Cr, EV/EBITDA: 6x
Simple DCF (5Y) dcf ₹2055.00 ₹1644.00 - ₹2466.00 +150.0% CF Growth: 15.0%, Discount: 15%
PEG Ratio Method growth ₹246.60 ₹221.94 - ₹271.26 -70.0% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹246.60 ₹221.94 - ₹271.26 -70.0% Revenue Growth: 6.0%, Adj P/E: 8.2x
ROE Based Valuation profitability ₹1280.00 ₹1152.00 - ₹1408.00 +55.7% ROE: 13.0%, P/E Multiple: 12x
Graham Defensive Method conservative ₹628.29 ₹565.46 - ₹691.12 -23.6% EPS: ₹21.32, BVPS: ₹822.92
Method Types: Earnings Asset DCF Growth Dividend Conservative

MEDPLUS Intrinsic Value vs Market Price — All Valuation Models

Medplus Health Services fair value range ₹247–₹2055 vs current market price ₹822.00 across 9 valuation models. Analyse Medplus Health Services shareholding analysis to track promoter, FII and institutional holdings.

MEDPLUS Intrinsic Value Analysis — Undervalued or Overvalued?

Medplus Health Services median intrinsic value ₹822.92, current price ₹822.00 — Trading Near Calculated Value by 0.1%, margin of safety 0.1%.

What is the intrinsic value of MEDPLUS?

Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Medplus Health Services (MEDPLUS) is ₹822.92 (median value). With the current market price of ₹822.00, this represents a +0.1% variance from our estimated fair value.

The valuation range spans from ₹246.60 to ₹2055.00, indicating ₹246.60 - ₹2055.00.

Is MEDPLUS undervalued or overvalued?

Based on our multi-method analysis, Medplus Health Services (MEDPLUS) appears to be trading near calculated value by approximately 0.1%.

MEDPLUS Financial Health — Key Ratios vs Industry Benchmarks

Medplus Health Services financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Current Ratio 1.63 Industry Standard: 2.0+ Above 1.5 Measures short-term liquidity capacity
Return on Equity 13.0% Industry Standard: 15%+ Above 10% Measures shareholder return efficiency
Operating Margin 9.0% Industry Standard: 20%+ Below 10% Indicates operational efficiency level
Asset Turnover Ratio 1.92x Industry Standard: 1.0x+ Above 1.0x Measures asset utilization efficiency

MEDPLUS Cash Flow Quality — Operating & Free Cash Flow

Medplus Health Services operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2025 ₹540 Cr ₹381 Cr Positive Free Cash Flow 8/10
March 2024 ₹144 Cr ₹103 Cr Positive Free Cash Flow 8/10
March 2023 ₹90 Cr ₹90 Cr Positive Free Cash Flow 8/10
March 2022 ₹170 Cr ₹-182 Cr Positive Operating Cash Flow 6/10
March 2021 ₹3 Cr ₹-15 Cr Positive Operating Cash Flow 6/10